260MO AGITG ASCEND study: Randomised, double-blind phase II study of certepetide (CERT) or placebo (PLA) added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC): Cohort B progression-free survival (PFS) results
Titel:
260MO AGITG ASCEND study: Randomised, double-blind phase II study of certepetide (CERT) or placebo (PLA) added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC): Cohort B progression-free survival (PFS) results
Auteur:
Dean, A. Harris, M. Sjoquist, K. Gebski, V. Karapetis, C.S. Lomma, C. Burge, M. Steer, C. Tebbutt, N.C. Lee, B. Jackson, C. Day, F. Padinharakam, S. Murray, J. Buck, K.K. Mumford, J.V. Siu, D. Lee, J. Gao, Y.R. Price, T.J.